Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

Antibody-Dependent, Gamma Interferon-Independent Sterilizing Immunity Induced by a Subunit Malaria Vaccine.

Chawla B, Mahajan B, Oakley M, Majam VF, Belmonte A, Sedegah M, Shimp RL Jr, Kaslow DC, Kumar S.

Infect Immun. 2019 Sep 19;87(10). pii: e00236-19. doi: 10.1128/IAI.00236-19. Print 2019 Oct.

PMID:
31308085
2.

Combining antimalarial drugs and vaccine for malaria elimination campaigns: a randomized safety and immunogenicity trial of RTS,S/AS01 administered with dihydroartemisinin, piperaquine, and primaquine in healthy Thai adult volunteers.

von Seidlein L, Hanboonkunupakarn B, Jittamala P, Pongsuwan P, Chotivanich K, Tarning J, Hoglund RM, Winterberg M, Mukaka M, Peerawaranun P, Sirithiranont P, Doran Z, Ockenhouse CF, Ivinson K, Lee C, Birkett AJ, Kaslow DC, Singhasivanon P, Day NPJ, Dondorp AM, White NJ, Pukrittayakamee S.

Hum Vaccin Immunother. 2019 Aug 15:1-9. doi: 10.1080/21645515.2019.1643675. [Epub ahead of print]

PMID:
31306084
3.

Pregnant women & vaccines against emerging epidemic threats: Ethics guidance for preparedness, research, and response.

Krubiner CB, Faden RR, Karron RA, Little MO, Lyerly AD, Abramson JS, Beigi RH, Cravioto AR, Durbin AP, Gellin BG, Gupta SB, Kaslow DC, Kochhar S, Luna F, Saenz C, Sheffield JS, Tindana PO; PREVENT Working Group.

Vaccine. 2019 May 3. pii: S0264-410X(19)30045-3. doi: 10.1016/j.vaccine.2019.01.011. [Epub ahead of print] Review.

4.

The role of immune correlates of protection on the pathway to licensure, policy decision and use of group B Streptococcus vaccines for maternal immunization: considerations from World Health Organization consultations.

Vekemans J, Crofts J, Baker CJ, Goldblatt D, Heath PT, Madhi SA, Le Doare K, Andrews N, Pollard AJ, Saha SK, Schrag SJ, Smith PG, Kaslow DC.

Vaccine. 2019 May 27;37(24):3190-3198. doi: 10.1016/j.vaccine.2019.04.039. Epub 2019 Apr 25. Review.

5.

Maternal interventions vigilance harmonization in low- and middle-income countries: Stakeholder meeting report; Amsterdam, May 1-2, 2018.

Sobanjo-Ter Meulen A, Munoz FM, Kaslow DC, Klugman KP, Omer SB, Vora P, Stergachis A.

Vaccine. 2019 May 6;37(20):2643-2650. doi: 10.1016/j.vaccine.2019.03.060. Epub 2019 Apr 4.

6.

The Path to Group A Streptococcus Vaccines: World Health Organization Research and Development Technology Roadmap and Preferred Product Characteristics.

Vekemans J, Gouvea-Reis F, Kim JH, Excler JL, Smeesters PR, O'Brien KL, Van Beneden CA, Steer AC, Carapetis JR, Kaslow DC.

Clin Infect Dis. 2019 Aug 16;69(5):877-883. doi: 10.1093/cid/ciy1143.

7.

Vaccine candidates for poor nations are going to waste.

Kaslow DC, Black S, Bloom DE, Datla M, Salisbury D, Rappuoli R.

Nature. 2018 Dec;564(7736):337-339. doi: 10.1038/d41586-018-07758-3. No abstract available.

PMID:
30560957
8.

Malaria vaccine candidate based on Duffy-binding protein elicits strain transcending functional antibodies in a Phase I trial.

Singh K, Mukherjee P, Shakri AR, Singh A, Pandey G, Bakshi M, Uppal G, Jena R, Rawat A, Kumar P, Bhardwaj R, Yazdani SS, Hans D, Mehta S, Srinivasan A, Anil K, Madhusudhan RL, Patel J, Singh A, Rao R, Gangireddy S, Patil R, Kaviraj S, Singh S, Carter D, Reed S, Kaslow DC, Birkett A, Chauhan VS, Chitnis CE.

NPJ Vaccines. 2018 Sep 28;3:48. doi: 10.1038/s41541-018-0083-3. eCollection 2018.

9.

WHO/IVI global stakeholder consultation on group A Streptococcus vaccine development: Report from a meeting held on 12-13 December 2016.

Osowicki J, Vekemans J, Kaslow DC, Friede MH, Kim JH, Steer AC.

Vaccine. 2018 Jun 7;36(24):3397-3405. doi: 10.1016/j.vaccine.2018.02.068. Epub 2018 Feb 26.

PMID:
29496349
10.

Maternal immunization against Group B streptococcus: World Health Organization research and development technological roadmap and preferred product characteristics.

Vekemans J, Moorthy V, Friede M, Alderson MR, Sobanjo-Ter Meulen A, Baker CJ, Heath PT, Madhi SA, Mehring-Le Doare K, Saha SK, Schrag S, Kaslow DC.

Vaccine. 2018 Feb 2. pii: S0264-410X(17)31359-2. doi: 10.1016/j.vaccine.2017.09.087. [Epub ahead of print] Review.

11.

WHO consultation on ETEC and Shigella burden of disease, Geneva, 6-7th April 2017: Meeting report.

Hosangadi D, Smith PG, Kaslow DC, Giersing BK; WHO ETEC & Shigella Vaccine Consultation Expert Group.

Vaccine. 2018 Jan 15. pii: S0264-410X(17)31376-2. doi: 10.1016/j.vaccine.2017.10.011. [Epub ahead of print]

PMID:
29352598
12.

Meeting report: Initial World Health Organization consultation on herpes simplex virus (HSV) vaccine preferred product characteristics, March 2017.

Gottlieb SL, Giersing BK, Hickling J, Jones R, Deal C, Kaslow DC; HSV Vaccine Expert Consultation Group.

Vaccine. 2017 Dec 7. pii: S0264-410X(17)31492-5. doi: 10.1016/j.vaccine.2017.10.084. [Epub ahead of print]

PMID:
29224963
13.

malERA: An updated research agenda for malaria elimination and eradication.

Rabinovich RN, Drakeley C, Djimde AA, Hall BF, Hay SI, Hemingway J, Kaslow DC, Noor A, Okumu F, Steketee R, Tanner M, Wells TNC, Whittaker MA, Winzeler EA, Wirth DF, Whitfield K, Alonso PL.

PLoS Med. 2017 Nov 30;14(11):e1002456. doi: 10.1371/journal.pmed.1002456. eCollection 2017 Nov. Review.

14.

Longitudinal estimation of Plasmodium falciparum prevalence in relation to malaria prevention measures in six sub-Saharan African countries.

Drakeley C, Abdulla S, Agnandji ST, Fernandes JF, Kremsner P, Lell B, Mewono L, Bache BE, Mihayo MG, Juma O, Tanner M, Tahita MC, Tinto H, Diallo S, Lompo P, D'Alessandro U, Ogutu B, Otieno L, Otieno S, Otieno W, Oyieko J, Asante KP, Dery DB, Adjei G, Adeniji E, Atibilla D, Owusu-Agyei S, Greenwood B, Gesase S, Lusingu J, Mahende C, Mongi R, Segeja M, Adjei S, Agbenyega T, Agyekum A, Ansong D, Bawa JT, Boateng HO, Dandalo L, Escamilla V, Hoffman I, Maenje P, Martinson F, Carter T, Leboulleux D, Kaslow DC, Usuf E, Pirçon JY, Bahmanyar ER.

Malar J. 2017 Oct 27;16(1):433. doi: 10.1186/s12936-017-2078-3.

15.

Vaccines to Accelerate Malaria Elimination and Eventual Eradication.

Healer J, Cowman AF, Kaslow DC, Birkett AJ.

Cold Spring Harb Perspect Med. 2017 Sep 1;7(9). pii: a025627. doi: 10.1101/cshperspect.a025627. Review.

16.

Meeting report: WHO consultation on Respiratory Syncytial Virus (RSV) vaccine development, Geneva, 25-26 April 2016.

Giersing BK, Karron RA, Vekemans J, Kaslow DC, Moorthy VS.

Vaccine. 2017 Mar 14. pii: S0264-410X(17)30293-1. doi: 10.1016/j.vaccine.2017.02.068. [Epub ahead of print]

17.

Report from the World Health Organization's third Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 8-10th June 2016.

Giersing BK, Vekemans J, Nava S, Kaslow DC, Moorthy V; WHO Product Development for Vaccines Advisory Committee.

Vaccine. 2017 Mar 2. pii: S0264-410X(16)31205-1. doi: 10.1016/j.vaccine.2016.10.090. [Epub ahead of print]

PMID:
28262332
18.

The role of vaccines and vaccine decision-making to achieve the goals of the Grand Convergence in public health.

Kaslow DC, Kalil J, Bloom D, Breghi G, Colucci AM, De Gregorio E, Madhavan G, Meier G, Seabrook R, Xu X.

Vaccine. 2017 Jan 20;35 Suppl 1:A10-A15. doi: 10.1016/j.vaccine.2016.10.088. Epub 2016 Dec 22.

PMID:
28017438
19.

WHO consultation on group B Streptococcus vaccine development: Report from a meeting held on 27-28 April 2016.

Kobayashi M, Schrag SJ, Alderson MR, Madhi SA, Baker CJ, Sobanjo-Ter Meulen A, Kaslow DC, Smith PG, Moorthy VS, Vekemans J.

Vaccine. 2016 Dec 22. pii: S0264-410X(16)31236-1. doi: 10.1016/j.vaccine.2016.12.029. [Epub ahead of print]

20.

Meeting Report: WHO consultation on considerations for regulatory expectations of Zika virus vaccines for use during an emergency.

Vannice KS, Giersing BK, Kaslow DC, Griffiths E, Meyer H, Barrett A, Durbin AP, Wood D, Hombach J.

Vaccine. 2016 Dec 20. pii: S0264-410X(16)30969-0. doi: 10.1016/j.vaccine.2016.10.034. [Epub ahead of print]

PMID:
27916410
21.

Seven-Year Efficacy of RTS,S/AS01 Malaria Vaccine among Young African Children.

Olotu A, Fegan G, Wambua J, Nyangweso G, Leach A, Lievens M, Kaslow DC, Njuguna P, Marsh K, Bejon P.

N Engl J Med. 2016 Jun 30;374(26):2519-29. doi: 10.1056/NEJMoa1515257.

22.

Fractional Third and Fourth Dose of RTS,S/AS01 Malaria Candidate Vaccine: A Phase 2a Controlled Human Malaria Parasite Infection and Immunogenicity Study.

Regules JA, Cicatelli SB, Bennett JW, Paolino KM, Twomey PS, Moon JE, Kathcart AK, Hauns KD, Komisar JL, Qabar AN, Davidson SA, Dutta S, Griffith ME, Magee CD, Wojnarski M, Livezey JR, Kress AT, Waterman PE, Jongert E, Wille-Reece U, Volkmuth W, Emerling D, Robinson WH, Lievens M, Morelle D, Lee CK, Yassin-Rajkumar B, Weltzin R, Cohen J, Paris RM, Waters NC, Birkett AJ, Kaslow DC, Ballou WR, Ockenhouse CF, Vekemans J.

J Infect Dis. 2016 Sep 1;214(5):762-71. doi: 10.1093/infdis/jiw237. Epub 2016 Jun 13.

PMID:
27296848
23.

Accelerating to Zero: Strategies to Eliminate Malaria in the Peruvian Amazon.

Quispe AM, Llanos-Cuentas A, Rodriguez H, Clendenes M, Cabezas C, Leon LM, Chuquiyauri R, Moreno M, Kaslow DC, Grogl M, Herrera S, Magill AJ, Kosek M, Vinetz JM, Lescano AG, Gotuzzo E.

Am J Trop Med Hyg. 2016 Jun;94(6):1200-1207. doi: 10.4269/ajtmh.15-0369.

24.

The 2016 Vaccine Development Pipeline: A special issue from the World Health Organization Product Development for Vaccine Advisory Committee (PDVAC).

Giersing BK, Modjarrad K, Kaslow DC, Okwo-Bele JM, Moorthy VS.

Vaccine. 2016 Jun 3;34(26):2863-2864. doi: 10.1016/j.vaccine.2016.04.041. Epub 2016 Apr 21. No abstract available.

25.

Report from the World Health Organization's Product Development for Vaccines Advisory Committee (PDVAC) meeting, Geneva, 7-9th Sep 2015.

Giersing BK, Modjarrad K, Kaslow DC, Moorthy VS; WHO Product Development for Vaccines Advisory Committee; WHO Product Development for Vaccines Product Development Advisory Committee:.

Vaccine. 2016 Jun 3;34(26):2865-2869. doi: 10.1016/j.vaccine.2016.02.078. Epub 2016 Mar 15.

26.

RTS,S: Toward a first landmark on the Malaria Vaccine Technology Roadmap.

Kaslow DC, Biernaux S.

Vaccine. 2015 Dec 22;33(52):7425-32. doi: 10.1016/j.vaccine.2015.09.061. Epub 2015 Oct 1. Review.

27.

WHO consultation on Respiratory Syncytial Virus Vaccine Development Report from a World Health Organization Meeting held on 23-24 March 2015.

Modjarrad K, Giersing B, Kaslow DC, Smith PG, Moorthy VS; WHO RSV Vaccine Consultation Expert Group.

Vaccine. 2016 Jan 4;34(2):190-197. doi: 10.1016/j.vaccine.2015.05.093. Epub 2015 Jun 20.

28.

Development of a transmission-blocking malaria vaccine: progress, challenges, and the path forward.

Nunes JK, Woods C, Carter T, Raphael T, Morin MJ, Diallo D, Leboulleux D, Jain S, Loucq C, Kaslow DC, Birkett AJ.

Vaccine. 2014 Sep 29;32(43):5531-9. doi: 10.1016/j.vaccine.2014.07.030. Epub 2014 Jul 29.

29.

Malaria vaccine R&D in the Decade of Vaccines: breakthroughs, challenges and opportunities.

Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC.

Vaccine. 2013 Apr 18;31 Suppl 2:B233-43. doi: 10.1016/j.vaccine.2013.02.040. Review.

PMID:
23598488
30.

Clostridium difficile and methicillin-resistant Staphylococcus aureus: emerging concepts in vaccine development.

Kaslow DC, Shiver JW.

Annu Rev Med. 2011;62:201-15. doi: 10.1146/annurev-med-051109-101544. Review.

PMID:
20707676
31.

Evaluation of a plasmid DNA-based anthrax vaccine in rabbits, nonhuman primates and healthy adults.

Keitel WA, Treanor JJ, El Sahly HM, Evans TG, Kopper S, Whitlow V, Selinsky C, Kaslow DC, Rolland A, Smith LR, Lalor PA.

Hum Vaccin. 2009 Aug;5(8):536-44. Epub 2009 Aug 14.

32.

Approaches to malaria vaccine development using the retrospectroscope.

Sardá V, Kaslow DC, Williamson KC.

Infect Immun. 2009 Aug;77(8):3130-40. doi: 10.1128/IAI.00122-09. Epub 2009 May 18. Review. No abstract available.

33.

Plasmid DNA-based vaccines protect mice and ferrets against lethal challenge with A/Vietnam/1203/04 (H5N1) influenza virus.

Lalor PA, Webby RJ, Morrow J, Rusalov D, Kaslow DC, Rolland A, Smith LR.

J Infect Dis. 2008 Jun 15;197(12):1643-52. doi: 10.1086/588431.

PMID:
18513153
34.

Induction of multi-antigen multi-stage immune responses against Plasmodium falciparum in rhesus monkeys, in the absence of antigen interference, with heterologous DNA prime/poxvirus boost immunization.

Jiang G, Charoenvit Y, Moreno A, Baraceros MF, Banania G, Richie N, Abot S, Ganeshan H, Fallarme V, Patterson NB, Geall A, Weiss WR, Strobert E, Caro-Aquilar I, Lanar DE, Saul A, Martin LB, Gowda K, Morrissette CR, Kaslow DC, Carucci DJ, Galinski MR, Doolan DL.

Malar J. 2007 Oct 9;6:135.

35.

Vaccination with polymerase chain reaction-generated linear expression cassettes protects mice against lethal influenza A challenge.

Vilalta A, Jimenez G, Rusalov D, Planchon R, Lalor P, Carner K, Chaplin JA, Komai M, Manthorpe M, Kaslow DC, Rolland A.

Hum Gene Ther. 2007 Aug;18(8):763-71.

PMID:
17705698
36.

Vaxfectin-formulated influenza DNA vaccines encoding NP and M2 viral proteins protect mice against lethal viral challenge.

Jimenez GS, Planchon R, Wei Q, Rusalov D, Geall A, Enas J, Lalor P, Leamy V, Vahle R, Luke CJ, Rolland A, Kaslow DC, Smith LR.

Hum Vaccin. 2007 Sep-Oct;3(5):157-64. Epub 2007 Mar 20.

PMID:
17637571
37.
38.

Qualification and performance characteristics of a quantitative enzyme-linked immunosorbent assay for human lgG antibodies to anthrax lethal factor antigen.

Selinsky CL, Whitlow VD, Smith LR, Kaslow DC, Horton HM.

Biologicals. 2007 Apr;35(2):123-9. Epub 2006 Oct 30.

PMID:
17071101
39.

Comparison of rabbit and mouse models for persistence analysis of plasmid-based vaccines.

Leamy VL, Martin T, Mahajan R, Vilalta A, Rusalov D, Hartikka J, Bozoukova V, Hall KD, Morrow J, Rolland AP, Kaslow DC, Lalor PA.

Hum Vaccin. 2006 May-Jun;2(3):113-8. Epub 2006 May 26.

PMID:
17012905
40.

Vaxfectin enhances immunogenicity and protective efficacy of P. yoelii circumsporozoite DNA vaccines.

Sedegah M, Rogers WO, Belmonte A, Belmonte M, Banania G, Patterson N, Ferrari M, Kaslow DC, Carucci DJ, Richie TL, Doolan DL.

Vaccine. 2006 Mar 10;24(11):1921-7. Epub 2005 Nov 2.

PMID:
16298024
41.

II. Cationic lipid-formulated plasmid DNA-based Bacillus anthracis vaccine: evaluation of plasmid DNA persistence and integration potential.

Vilalta A, Mahajan RK, Hartikka J, Leamy V, Martin T, Rusalov D, Bozoukova V, Lalor P, Hall K, Kaslow DC, Rolland A.

Hum Gene Ther. 2005 Oct;16(10):1151-6.

PMID:
16218776
42.

I. Poloxamer-formulated plasmid DNA-based human cytomegalovirus vaccine: evaluation of plasmid DNA biodistribution/persistence and integration.

Vilalta A, Mahajan RK, Hartikka J, Rusalov D, Martin T, Bozoukova V, Leamy V, Hall K, Lalor P, Rolland A, Kaslow DC.

Hum Gene Ther. 2005 Oct;16(10):1143-50.

PMID:
16218775
43.
44.

CpG oligodeoxynucleotide and Montanide ISA 51 adjuvant combination enhanced the protective efficacy of a subunit malaria vaccine.

Kumar S, Jones TR, Oakley MS, Zheng H, Kuppusamy SP, Taye A, Krieg AM, Stowers AW, Kaslow DC, Hoffman SL.

Infect Immun. 2004 Feb;72(2):949-57.

45.

Comparative analysis of the effects of packaging signal, transgene orientation, promoters, polyadenylation signals, and E3 region on growth properties of first-generation adenoviruses.

Youil R, Toner TJ, Su Q, Casimiro D, Shiver JW, Chen L, Bett AJ, Rogers BM, Burden EC, Tang A, Chen M, Emini EA, Kaslow DC, Aunins JG, Altaras NE.

Hum Gene Ther. 2003 Jul 1;14(10):1017-34.

PMID:
12869219
46.

The effects of varying exposure to malaria transmission on development of antimalarial antibody responses in preschool children. XVI. Asembo Bay Cohort Project.

Singer LM, Mirel LB, ter Kuile FO, Branch OH, Vulule JM, Kolczak MS, Hawley WA, Kariuki SK, Kaslow DC, Lanar DE, Lal AA.

J Infect Dis. 2003 Jun 1;187(11):1756-64. Epub 2003 May 12.

PMID:
12751033
47.

Development of an adenovirus-shedding assay for the detection of adenoviral vector-based vaccine and gene therapy products in clinical specimens.

Wang F, Patel DK, Antonello JM, Washabaugh MW, Kaslow DC, Shiver JW, Chirmule N.

Hum Gene Ther. 2003 Jan 1;14(1):25-36.

PMID:
12573056
48.

A high malaria reinfection rate in children and young adults living under a low entomological inoculation rate in a periurban area of Bamako, Mali.

Sagara I, Sangaré D, Dolo G, Guindo A, Sissoko M, Sogoba M, Niambélé MB, Yalcoué D, Kaslow DC, Dicko A, Klion AD, Diallo D, Miller LH, Touré Y, Doumbo O.

Am J Trop Med Hyg. 2002 Mar;66(3):310-3.

PMID:
12139226
49.

Short report: differential evolution of immunoglobulin G1/G3 antibody responses to Plasmodium falciparum MSP1(19) over time in malaria-immune adult Senegalese patients.

Diallo TO, Spiegel A, Diouf A, Lochouarn L, Kaslow DC, Tall A, Perraut R, Garraud O.

Am J Trop Med Hyg. 2002 Feb;66(2):137-9.

PMID:
12135282
50.

Transmission-blocking vaccines.

Kaslow DC.

Chem Immunol. 2002;80:287-307. Review. No abstract available.

PMID:
12058646

Supplemental Content

Loading ...
Support Center